Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) EBITDA: 2011-2025

Historic EBITDA for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$5.1 million.

  • Abeona Therapeutics' EBITDA rose 83.10% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 216.09%. This contributed to the annual value of -$63.7 million for FY2024, which is 17.62% down from last year.
  • Abeona Therapeutics' EBITDA amounted to -$5.1 million in Q3 2025, which was down 104.69% from $108.9 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' EBITDA ranged from a high of $108.9 million in Q2 2025 and a low of -$46.7 million during Q4 2021.
  • Over the past 3 years, Abeona Therapeutics' median EBITDA value was -$11.8 million (recorded in 2023), while the average stood at -$2.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 250.50% in 2024, then surged by 1,359.97% in 2025.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' EBITDA stood at -$46.7 million in 2021, then skyrocketed by 84.57% to -$7.2 million in 2022, then slumped by 129.78% to -$16.6 million in 2023, then soared by 44.43% to -$9.2 million in 2024, then skyrocketed by 83.10% to -$5.1 million in 2025.
  • Its EBITDA was -$5.1 million in Q3 2025, compared to $108.9 million in Q2 2025 and -$12.1 million in Q1 2025.